Description de l'entreprise
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk markets its products in more than 180 countries.
Conseil d'administration & Conseil de surveillance
| PDG |
| Lars Fruergaard Jørgensen |
| Conseil d'administration |
| Karsten Munk Knudsen, Camilla Sylvest, Doug Langa, Henrik Wulff, Ludovic Helfgott, Marcus Schindler, Martin Horst Lange, Maziar Mike Doustdar, Monique Carter, David Moore |
| Conseil de surveillance |
| Helge Lund, Andreas Fibig, Henrik Poulsen, Kasim Kutay, Laurence Debroux, Martin Mackay, Mette Bøjer Jensen, Sylvie Grégoire, Thomas Rantzau, Elisabeth Dahl Christensen, Liselotte Hyveled, Christina Law |
Données de l'entreprise
| Nom: |
Novo Nordisk AS |
| Adresse: |
Novo Allé,DK-2880 Bagsværd |
| Téléphone: |
+45-4444-8888 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
www.novonordisk.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
66.64% |
| IPO date: |
- |
